ClinConnect ClinConnect Logo
Search / Trial NCT04804813

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

Launched by TAKEDA · Mar 16, 2021

Trial Information

Current as of June 17, 2025

Completed

Keywords

ClinConnect Summary

The drug being tested in this study is called cabozantinib tablets. This tablet is being tested to treat people who have radically unresectable or metastatic renal cell carcinoma.

This study is an observational (non-interventional) study and will look at occurrence of adverse drug reactions (or adverse events) of cabozantinib tablets in the routine clinical setting. The planned number of observed patients will be approximately 300.

This multi-center observational trial will be conducted in Japan.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with radically unresectable or metastatic renal cell carcinoma who do not meet the following exclusion criterion are eligible.
  • Exclusion Criteria:
  • A patient who has a history of hypersensitivity to any component of cabozantinib.

About Takeda

Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical organization committed to advancing patient care through innovative therapies. Founded in 1781 and headquartered in Osaka, Japan, Takeda focuses on key therapeutic areas including oncology, gastroenterology, neuroscience, and rare diseases. With a strong emphasis on research and development, Takeda leverages cutting-edge science and technology to deliver transformative medicines that address unmet medical needs. The company is dedicated to sustainability and ethical practices, ensuring that its clinical trials uphold the highest standards of safety and efficacy while fostering collaboration with healthcare professionals and communities worldwide.

Locations

Tokyo, , Japan

Patients applied

0 patients applied

Trial Officials

Study Director

Study Director

Takeda

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials